BioSpace News Archive

PumasAI, a pioneering organization at the forefront of transforming data into life-saving decisions with remarkable speed, is proud to announce the appointment of two distinguished leaders to its team.

Gold Colloid Co., a leading distributor of medical and diagnostic products in the United States, announced today a strategic partnership with Hangzhou Clongene Biotech Co., Ltd., a renowned Chinese manufacturer of in-vitro diagnostic (IVD) rapid tests and raw materials.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) submitted a comment letter (here) on January 5, 2024, regarding the FDA’s recently announced policy—by way of a draft guidance document—that substantially restricts drug manufacturers’ ability to communicate truthful, non-misleading information about FDA-approved drugs.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a fireside chat at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 18, 2024 at 1:00 p.m. ET.

Centene Corporation announced today it has completed the previously announced divestiture of Circle Health Group, one of the U.K.'s largest independent operators of hospitals, to Pure Health, the largest integrated healthcare network in the Middle East.

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company focused on the development of Superkines, announced the appointment of MNP LLP as auditor.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Rhythm Pharmaceuticals, Inc. announced that on January 9, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 13,020 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 8,680 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 4,340 shares of its common stock.

Ardelyx, Inc. announced that on January 10, 2024, the compensation committee of the company’s board of directors granted two new non-executive employees options to purchase an aggregate of 23,580 shares of the company’s common stock, and granted three new non-executive employees an aggregate of 33,300 Restricted Stock Units.

Geneoscopy, Inc. announced that it has petitioned the United States Patent and Trademark Office for inter partes review challenging the patentability of United States Patent No. 11,634,781 owned by Exact Sciences.